In the company’s news yesterday,
Millennium Biotechnologies Group announced that Nutrimedica, S.A., an international nutritional supplement distributor, headquartered in Athens, Greece, has ordered its complete medical line which includes 5 separate Resurgex(r) product lines and 12 SKUs of the Company’s powdered and Ready-To-Drink formulations. The purchase order, greater than the total revenue the Company received from Greece in 2008, is valued at $487,690 and will be shipped during the first quarter of 2009.
Chief Executive Officer Mark Mirken stated, “The strong broad-based demand for the Resurgex product line in Greece supports and encourages our expectation that the product line will be successful in the international marketplace as a whole. We plan to add additional international distributors of similar size this year. Importantly, Nutrimedica has been successful in broadening the usage of the Resurgex product line beyond Oncology, into other hospital settings including Intensive Care Units and Surgery Clinics as well as the retail marketplace in Greece.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
